[go: up one dir, main page]

WO2004008137A3 - Methode de diagnostic et de traitement de tumeurs du sein resistant au traitement anti-estrogene - Google Patents

Methode de diagnostic et de traitement de tumeurs du sein resistant au traitement anti-estrogene Download PDF

Info

Publication number
WO2004008137A3
WO2004008137A3 PCT/EP2003/007449 EP0307449W WO2004008137A3 WO 2004008137 A3 WO2004008137 A3 WO 2004008137A3 EP 0307449 W EP0307449 W EP 0307449W WO 2004008137 A3 WO2004008137 A3 WO 2004008137A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiestrogen
protein
antiestrogen treatment
treatment
breast tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/007449
Other languages
English (en)
Other versions
WO2004008137A2 (fr
Inventor
Iduna Fichtner
Michael Becker
Perez Vladimir Besada
Serra Lila Castellanos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10310198A external-priority patent/DE10310198A1/de
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB, Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority to AU2003253050A priority Critical patent/AU2003253050A1/en
Publication of WO2004008137A2 publication Critical patent/WO2004008137A2/fr
Publication of WO2004008137A3 publication Critical patent/WO2004008137A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une méthode de diagnostic et de traitement de tumeurs du sein résistant à un traitement anti-estrogène, au moyen de protéines cibles spécifiques et des acides nucléiques codant pour ces dernières. Ladite méthode est basée sur la détermination de l'expression différentielle de gènes cibles spécifiques sur les acides nucléiques et du niveau de protéines dans des cellules de tumeurs du sein résistant au traitement anti-estrogène. Ladite méthode trouve des application en médecine et dans l'industrie pharmaceutique. Ladite méthode se caractérise en ce que la concentration d'au moins une protéine cible spécifique est déterminée dans le tissu de la tumeur et est comparée à la valeur de référence standard de la ou des mêmes protéines dans le tissu de tumeur du sein sensible au traitement anti-estrogène. Une concentration de protéine dans l'échantillon examiné supérieure à la valeur de référence standard indique une résistance de la tumeur au traitement anti-estrogène, s'il s'agit d'une protéine exprimée à des niveaux supérieurs dans des cellules de tumeur du sein résistant au traitement anti-estrogène, par rapport aux cellules de tumeur du sein sensibles au traitement anti-estrogène ; ou une concentration de protéine dans l'échantillon examiné inférieure à la valeur de référence standard indique la résistance de la tumeur au traitement anti-estrogène, s'il s'agit d'une protéine exprimée à un niveau inférieur dans les cellules de tumeur du sein résistant au traitement anti-estrogène, par rapport aux cellules de tumeurs du sein sensibles au traitement anti-estrogène.
PCT/EP2003/007449 2002-07-12 2003-07-10 Methode de diagnostic et de traitement de tumeurs du sein resistant au traitement anti-estrogene Ceased WO2004008137A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003253050A AU2003253050A1 (en) 2002-07-12 2003-07-10 Diagnosis and therapy of breast tumours resistant to antiestrogen treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10231873.5 2002-07-12
DE10231873 2002-07-12
DE10310198A DE10310198A1 (de) 2002-07-12 2003-03-06 Verfahren zur Diagnose und Therapie von antiöstrogentherapieresistenten Brusttumoren
DE10310198.5 2003-03-06

Publications (2)

Publication Number Publication Date
WO2004008137A2 WO2004008137A2 (fr) 2004-01-22
WO2004008137A3 true WO2004008137A3 (fr) 2004-09-02

Family

ID=30116640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007449 Ceased WO2004008137A2 (fr) 2002-07-12 2003-07-10 Methode de diagnostic et de traitement de tumeurs du sein resistant au traitement anti-estrogene

Country Status (2)

Country Link
AU (1) AU2003253050A1 (fr)
WO (1) WO2004008137A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502891A (ja) * 2004-06-18 2008-01-31 エフ．ホフマン−ラ　ロシュ　アーゲー 乳癌のマーカーとしてのタンパク質ｐｄｘ１の使用
CN102346190A (zh) * 2011-01-24 2012-02-08 中国人民解放军第三军医大学 用于检测生物标本中的过氧化物还原酶ⅳ的双抗夹心elisa试剂盒及其方法与运用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001063292A2 (fr) * 2000-02-22 2001-08-30 Board Of Regents, The University Of Texas System Compositions et utilisations de het, un nouveau modulateur de l'action oestrogenique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001063292A2 (fr) * 2000-02-22 2001-08-30 Board Of Regents, The University Of Texas System Compositions et utilisations de het, un nouveau modulateur de l'action oestrogenique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERGGREN MARGARETA I ET AL: "Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 392, no. 1, 1 August 2001 (2001-08-01), pages 103 - 109, XP002266115, ISSN: 0003-9861 *
HILSENBECK S G ET AL: "STATISTICAL ANALYSIS OF ARRAY EXPRESSION DATA AS APPLIED TO THE PROBLEM OF TAMOXIFEN RESISTANCE", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 91, no. 5, 26 January 1999 (1999-01-26), pages 453 - 459, XP009002755, ISSN: 0027-8874 *
KARIHTALA PEETER ET AL: "Peroxiredoxins in breast carcinoma.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES 15 AUG 2003, vol. 9, no. 9, 15 August 2003 (2003-08-15), pages 3418 - 3424, XP002266133, ISSN: 1078-0432 *
NOH DONG-YOUNG ET AL: "Overexpression of peroxiredoxin in human breast cancer", ANTICANCER RESEARCH, vol. 21, no. 3B, May 2001 (2001-05-01), pages 2085 - 2090, XP008026146, ISSN: 0250-7005 *
SEITH P ET AL: "Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression)", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 21, 23 January 2002 (2002-01-23), pages 836 - 843, XP002965930, ISSN: 0950-9232 *
SHOU J ET AL: "Onset of endocrine resistance in breast cancer is associated with increased actibe p38 MAPK", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 69, no. 3, October 2001 (2001-10-01), pages 254, XP002960169, ISSN: 0167-6806 *

Also Published As

Publication number Publication date
AU2003253050A1 (en) 2004-02-02
AU2003253050A8 (en) 2004-02-02
WO2004008137A2 (fr) 2004-01-22

Similar Documents

Publication Publication Date Title
Dobashi et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas
WO2004110345A8 (fr) Genes exprimes de maniere differenciee impliques dans le cancer, polypeptides codes par ces genes, et methodes d'utilisation des genes
WO2001000828A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du poumon
HK1045332A1 (zh) 用於治療和診斷肺癌的化合物及其使用方法
WO2001096388A3 (fr) Compositions et procedes servant a traiter et a diagnostiquer le cancer du colon
WO2001096390A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2001079286A3 (fr) Compositions et procedes de traitement et de diagnostic du cancer du sein
JP2015210268A5 (fr)
WO2001073027A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2005098046A3 (fr) Methodes de determination de biomarqueurs specifiques de cellules
WO2005005661A3 (fr) Genes regules dans le cancer de l'ovaire utilises comme cibles pronostique et therapeutique
WO2002078526A3 (fr) Antigenes vis-a-vis du cancer du testicule
WO2005000335A3 (fr) Procedes de diagnostic et de traitement lies au vieillissement, en particulier au vieillissement du foie
Devaraj Salivary biomarkers-a review
KR101720050B1 (ko) 폐암관련 돌연변이 증폭용 프라이머 세트, 및 상기 돌연변이에 상보적인 프로브를 포함하는, 폐암 진단용 키트
WO2004008137A3 (fr) Methode de diagnostic et de traitement de tumeurs du sein resistant au traitement anti-estrogene
WO2006081248A3 (fr) Marqueurs du cancer et procedes de detection
WO2004053075A3 (fr) Compositions, variants d'epissage et procedes relatifs a des genes et des proteines specifiques du sein
WO2007020522A3 (fr) Marqueurs proteiniques permettant de diagnostiquer un cancer colorectal et utilisation de ces marqueurs comme cibles de medicament en vue du traitement de ce type de cancer
CN105087794A (zh) 一种检测结核病的试剂盒
WO2003076578A3 (fr) Polypeptides therapeutiques, acides nucleiques codant pour eux et leur procede d'utilisation
WO2002002623A3 (fr) Compositions et methodes de diagnostic et de traitement du cancer des poumons
WO2002099421A3 (fr) Jeux ordonnes de microechantillons specifiques destines a la detection du cancer du sein
Tanaka et al. PATH-28. Clinical and genetic characteristics of diffuse midline glioma in the spinal cord
WO2002012332A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP